CN105641689A - Preparing method and application of dairy cattle staphylococcus aureus beta-hemolysin subunit vaccine - Google Patents
Preparing method and application of dairy cattle staphylococcus aureus beta-hemolysin subunit vaccine Download PDFInfo
- Publication number
- CN105641689A CN105641689A CN201610068816.7A CN201610068816A CN105641689A CN 105641689 A CN105641689 A CN 105641689A CN 201610068816 A CN201610068816 A CN 201610068816A CN 105641689 A CN105641689 A CN 105641689A
- Authority
- CN
- China
- Prior art keywords
- beta
- hemolysin
- staphylococcus aureus
- subunit vaccine
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 29
- 229940031626 subunit vaccine Drugs 0.000 title claims abstract description 21
- 235000013365 dairy product Nutrition 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title abstract description 8
- 101000730486 Staphylococcus aureus Phospholipase C Proteins 0.000 title abstract 3
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 25
- 239000003228 hemolysin Substances 0.000 claims abstract description 24
- 208000004396 mastitis Diseases 0.000 claims abstract description 22
- 101710124951 Phospholipase C Proteins 0.000 claims abstract description 16
- 239000002671 adjuvant Substances 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 238000000746 purification Methods 0.000 claims abstract description 6
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 5
- 239000013604 expression vector Substances 0.000 claims abstract description 4
- 206010018910 Haemolysis Diseases 0.000 claims description 23
- 230000008588 hemolysis Effects 0.000 claims description 23
- 241000894006 Bacteria Species 0.000 claims description 21
- 238000002703 mutagenesis Methods 0.000 claims description 15
- 231100000350 mutagenesis Toxicity 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 12
- 235000013336 milk Nutrition 0.000 claims description 11
- 239000008267 milk Substances 0.000 claims description 11
- 210000004080 milk Anatomy 0.000 claims description 11
- 108010022355 Fibroins Proteins 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 101710194807 Protective antigen Proteins 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 230000008034 disappearance Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract 4
- 230000006798 recombination Effects 0.000 abstract 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract 2
- 238000002741 site-directed mutagenesis Methods 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 229910052759 nickel Inorganic materials 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 27
- 229960005486 vaccine Drugs 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 108010006464 Hemolysin Proteins Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000000246 agarose gel electrophoresis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a preparing method and application of a dairy cattle staphylococcus aureus beta-hemolysin subunit vaccine, and aims at providing a preparing method for a subunit vaccine for preventing or treating dairy cattle staphylococcus aureus mastitis. The preparing method comprises the following steps that firstly, a staphylococcus aureus beta-hemolysin protein gene is subjected to site-specific mutagenesis; secondly, the beta-hemolysin protein gene subjected to site-specific mutagenesis is cloned into a pET28a vector; thirdly, the expression vector obtained in the second step is converted into E.coli BL21(DE3), and recombination beta-hemolysin protein is obtained through induction expression; fourthly, the recombination beta-hemolysin protein obtained in the third step is purified through nickel column affinity chromatography; fifthly, the recombination beta-hemolysin protein obtained through purification is fully mixed with a medically-acceptable adjuvant, and the recombination subunit vaccine for dairy cattle staphylococcus aureus mastitis is obtained.
Description
Technical field
The present invention relates to the preparation method of the subunit vaccine of a kind of staphylococcus aureus mastitis in dairy cows and application. Belong to biovaccine preparing technical field.
Background technology
Mammitis of cow (Mastitis) is the most general infectious diseases of adult milk cow, a kind of inflammation that mainly cow mammary gland tissue is subject to infected by microbes and cause, multiple it is born in lactation in postpartum, this disease is extensively present in all over the world, for milk cow common disease, frequently-occurring disease, it it is the disease causing milk-product industry financial loss the most serious. Cause the nearly kind more than 150 of the pathogenic micro-organism of mammitis of cow, main based on streptococcus aureus, intestinal bacteria, streptococcus agalactiae, these three kinds thin microbial mammitis of cow account for more than the 90% of total incidence, wherein especially taking streptococcus aureus as.
The methods for the treatment of of current mammitis of cow mainly adopts antibiotic therapy, microbiotic is used for the treatment of the mammitis of cow history of existing more than 50 year, it plays certain effect in the control of mammitis of cow, but due to not scientifical use microbiotic single, heavy dose of for a long time, cause the elimination of sensitive bacteria, drug tolerant bacteria account for main flow gradually, and especially the resistance problems of streptococcus aureus is day by day serious, result in antibiotic therapy and produces little effect.
Preventing and treating mammitis of cow with vaccine and have good prospect, first, vaccine can prevent milk cow infection pathogen and cause mastitis; Secondly, vaccine contributes to reducing the severity of intramammary infection, controls subclinical type mastitis; 3rd, it may also be useful to vaccine control mastitis there will be no antibiotic remains problem in milk; Being finally easy and simple to handle, expense is cheap. Currently; the vaccine succeeded in developing is little; and mostly number is weak poison live vaccine or inactivated vaccine; in production practice, the control of mastitis there is is certain effect, but the development along with extensive intensive culture; the exquisite weak bacterial strain of people also exists homologous recombination, self virulence returns the potential possibilities such as strong; and inactivated vaccine also exists the deficiencies such as using dosage is big, duration of immunity is short, for improving security and the immune protective efficiency of traditional vaccine, efficient, cheap new generation vaccine development is extremely important.
Streptococcus aureus (Staphylococcusaureus is called for short SA), also claims " S. aureus L-forms ", being the coccus of a kind of Gram-positive, diameter 0.8 ��m, is arranged in thyrsiform under the microscope, and golden yellow pigment can be produced, and therefore gain the name. S. aureus L-forms is one of the main pathogenic fungi causing chronic/recessive mammitis of cow, it is possible to affects the seed output and quality of milk greatly, brings huge financial loss to dairy industry. There are some researches show, the �� hemolysin of streptococcus aureus secretion is the virulence factor causing mammitis of cow.
S. aureus L-forms can produce multiple toxin and enzyme. �� hemolysin (also known as ��-toxin) is exactly one of its toxin, and it has the characteristic such as leucocytotoxicity, hemolytic activity. The single chain polypeptide that �� hemolysin is made up of 330 amino acid, molecular weight is 37��39kDa, and its iso-electric point (pI) is higher than 9. �� hemolysin is that a kind of magnesium relies on neural esterase, there is Phospholipase C (PhospholipaseC, PLC) active, Glycerophosphorylcholine can be decomposed, �� hemolysin relies on this kind of enzymic activity, the phospholipid bilayer of hydrolysis composition cytolemma, thus destroys the integrity of cytolemma, cause lysis, cause haemolysis. After �� hemolysin is carried out rite-directed mutagenesis, mutant just loses hemolytic activity, does not have toxicity, but still retains intact immunogenicity, can directly be used for immune animal, is one of the important candidate albumen of S. aureus L-forms subunit vaccine.
Summary of the invention
It is an object of the invention to provide the preparation method of a kind of milk cow streptococcus aureus beta hemolysis element subunit vaccine and application. Recombinant protein mixes the subunit vaccine of preparation and the natural infection similar process of pathogenic bacterium with suitable adjuvant; cellular immunization can be promoted; inducing immunological memory and cause immunne response widely; produce the reaction of good cross protection, it is a kind of safety and stability more, prepare new generation vaccine simple, that application is convenient, cheap.
Described recombinant beta-hemolysin albumen is from streptococcus aureus, and the nucleotide sequence encoding this albumen is as shown in SEQIDNO.2.
The present invention also provides the preparation method of a kind of milk cow streptococcus aureus beta hemolysis element subunit vaccine, mainly comprises the following steps: 1) rite-directed mutagenesis streptococcus aureus beta hemolysis fibroin gene; 2) by the beta hemolysis fibroin gene clone of rite-directed mutagenesis in pET28a carrier; 3) by step 2) the expression vector Transformed E .coliBL21 (DE3) that obtains, abduction delivering obtains recombinant beta-hemolysin albumen; 4) affinity chromatography purification step 3 is used) recombinant beta-hemolysin albumen of obtaining; 5) staphylococcus aureus mastitis in dairy cows recombinant subunit vaccine is obtained after the recombinant beta obtained by purifying-hemolysin albumen and pharmaceutically acceptable adjuvant (such as ISA206VG adjuvant) are fully mixed even.
Compared with prior art; the advantage that the present invention has and effect are as follows: the protective immunity that namely mammitis of cow subunit vaccine utilizes pathogenic bacterium main is former to be made not containing nucleic acid, the vaccine that can bring out body and produce antibody; it is directly injected body and activating immune system, to reach the object of prevention and therapy disease. Recombinant protein mixes the subunit vaccine of preparation and the natural infection similar process of pathogenic bacterium with suitable adjuvant; cellular immunization can be promoted; inducing immunological memory and cause immunne response widely; produce the reaction of good cross protection; be one more safety and stability, preparation is simple, application is convenient, cheap, and the time saving and energy saving new generation vaccine with significant curative effect.
Accompanying drawing explanation
Fig. 1, beta hemolysis element segmented-PCR product agarose gel electrophoresis result, M:MarkerDL2,000; 1 is �� hemolysin rite-directed mutagenesis fragment 1 (509bp), and 2 is �� hemolysin rite-directed mutagenesis fragment 2 (468bp).
Fig. 2, beta hemolysis element rite-directed mutagenesis over-lap PCR agarose gel electrophoresis result, M:MarkerDL5,000; 1 is �� hemolysin rite-directed mutagenesis overlapping PCR products (936bp).
Fig. 3, beta hemolysis element rite-directed mutagenesis recombinant plasmid enzyme cuts qualification agarose gel electrophoresis result, M:MarkerDL5,000; 1 is pET28a-�� hemolysin rite-directed mutagenesis No. 3 plasmids (NdeI/XhoI), and 2 is pET28a-�� hemolysin rite-directed mutagenesis No. 4 plasmids (NdeI/XhoI).
Fig. 4, beta hemolysis element affinity chromatography purification result, FT:flowthrough; 50mM:50mM imidazoles; 100mM:100mM imidazoles; 150mM:150mM imidazoles.
Fig. 5, recombinant beta-hemolysin protein renaturation result.
Fig. 6, ELISA tire result after detecting beta hemolysis element subunit vaccine immune mouse.
Mouse survival rate experimental result after Fig. 7, Immunization.
Embodiment
The structure of embodiment 1 expression vector pET28a-beta hemolysis element rite-directed mutagenesis
Taking the clinical milk cow staphylococcus aureus gene group being separated to as template, beta hemolysis element being divided into two sections and carries out PCR, result is as shown in Figure 1.
1.1 add sample system for (50 �� l):
1.2PCR amplification program:
1.3 glue reclaim DNA fragmentation:
(1) reaction solution of step 1.2 is carried out 0.8% agarose gel electrophoresis (110V30min);
(2) under ultraviolet lamp, cut glue and reclaim DNA fragmentation in 1.5mlEP pipe;
(3) in the 1.5mlEP pipe in step (2), 500 �� lPCbuffer are added, 50 DEG C, water-bath 10min;
(4) solution in step (3) is moved to adsorption column center, leave standstill 2min, centrifugal, 12,000rpm, 30s;
(5) abandon waste liquid, add 600 �� lPWbuffer to adsorption column center, leave standstill 3min, 12,000rpm, 30s;
(6) repeating step (5);
(7) suction attached column is centrifugal, 12,000rpm, 1min;
(8) 30 �� lddH are added to adsorption column center2O, leaves standstill 3min, centrifugal (12,000rpm, 2min);
(9) collect step (8) DNA sample and carry out electrophoresis.
1.4 over-lap PCR, carry out rite-directed mutagenesis by beta hemolysis element, result as shown in Figure 2:
Add sample system for (50 �� l):
Pcr amplification program:
1.5 double digestions reaction (50 �� l system):
1.5mlEP pipe carries out according to step 1.5 adding sample, mixed even, then these two 50 �� l reaction solutions is placed in 37 DEG C of thermostat water baths, water-bath 3h.
1.6 glue reclaim DNA fragmentation:
(1) reaction solution of step 1.5 is carried out 0.8% agarose gel electrophoresis (110V30min);
(2) under ultraviolet lamp, cut glue and reclaim DNA fragmentation in 1.5mlEP pipe;
(3) in the 1.5mlEP pipe in step (2), 500 �� lPCbuffer are added, 50 DEG C, water-bath 10min;
(4) solution in step (3) is moved to adsorption column center, leave standstill 2min, centrifugal, 12,000rpm, 30s;
(5) abandon waste liquid, add 600 �� lPWbuffer to adsorption column center, leave standstill 3min, 12,000rpm, 30s;
(6) repeating step (5);
(7) suction attached column is centrifugal, 12,000rpm, 1min;
(8) 30 �� lddH are added to adsorption column center2O, leaves standstill 3min, centrifugal (12,000rpm, 2min);
(9) collect step (8) DNA sample and carry out electrophoresis.
1.7 ligations (10 �� l system):
1.5mlEP pipe carries out according to above-mentioned system adding sample, mixed even, then above-mentioned reaction solution is placed in 16 DEG C, takes out after water-bath 16h, 65 DEG C, after water-bath 15min, carry out deactivation, by the preservation of 4 DEG C, sample.
1.8 transformation experiments:
(1) take out the reaction solution of step 1.7, add 100 �� lE.coliDH5 �� competent cells wherein, mixed even;
(2) ice bath 30min;
(3) 42 DEG C, water-bath 100s;
(4) ice bath 2min;
(5) take out, in EP pipe, add 600 �� l LB liquid medium, 37 DEG C, water-bath 1h;
(6) taking out, centrifugal (8,000rpm, 2min), removes 600 �� l, remains the 100 resuspended thalline of �� lLB;
(7) getting bacterium liquid is plated in LK flat board (Kan concentration is 50 �� g/ml), and LK flat board is placed in biochemical constant incubator, cultivates 12h for 37 DEG C.
1.9 recombinant plasmids extract and enzyme cuts qualification:
(1) choose from transformation plate and get mono-clonal to, in 3mlLK liquid nutrient medium, 37 DEG C, 260rpm shakes bacterium and spends the night;
(2) 1ml bacterium liquid is got to, in 1.5mlEP pipe, centrifugal (12,000rpm, 2min), abandons supernatant;
(3) in the EP pipe in step (2), 250 �� lP1buffer are added, resuspended thalline;
(4) in step (3) solution, 250 �� lP2buffer are added, gentle mixed even, leave standstill 2min;
(5) in step (4) solution, 350 �� lP3buffer are added, gentle mixed even;
(6) by step (5) solution, centrifugal (12,000rpm, 10min);
(7) supernatant solution in step (6) is moved to adsorption column center, centrifugal (8,000g, 30s);
(8) abandon waste liquid, add 500 �� lwashbuffer to adsorption column center, centrifugal (9,000g, 30s);
(9) repeating step (8);
(10) suction attached column centrifugal (9,000g, 1min);
(11) adsorption column adds 30 �� lElutionbuffer, leaves standstill 2min, centrifugal (12,000rpm, 2min);
(12) collect step (11) DNA sample and carry out electrophoresis;
(13) as shown in step 1.5, the plasmid extracted is carried out enzyme and cuts qualification, then carry out 0.8% agarose gel electrophoresis.
Recombinant plasmid enzyme is cut qualification result and is seen Fig. 3.
Embodiment 2 transformation of E. coli BL21
Drawing 1 �� l plasmid adds in 100 �� lBL21 competent cells, ice bath 30min;
42 DEG C of heat shock 90s;
Ice bath 2min;
The LB nutrient solution of 900 �� l non-resistants is added in super clean bench;
37 DEG C of 180rpm shake 1h;
Draw that resistance LB of 100 �� l bacterium liquid card-coatings dull and stereotyped, 37 DEG C of incubated overnight.
The a large amount of abduction delivering of embodiment 3
Choose bacterium: choose and get mono-clonal in that resistance LB nutrient solution of 50ml card, 37 DEG C of incubated overnight;
Switching: in 1: 100 ratio switching bacterium liquid to that resistance LB nutrient solution of 500ml card, shaking 3.5L altogether, 37 DEG C of 220rpm cultivate 2-2.5h to OD600Value is to 0.6;
Induction: bacterium liquid OD600Being worth after 0.6, adding 500 �� lIPTG (1M) is 1mmol/L to IPTG final concentration, 37 DEG C of 220rpm inducing culture 4h;
Microorganism collection: the centrifugal 10min of bacterium liquid 6,000rpm, collects thalline; Clean thalline with 40mlPBS, the centrifugal 10min of 6,000rpm, collect thalline, be placed in-20 DEG C of preservations;
Prepared by embodiment 4 beta hemolysis fibroin inclusion body
(1) bacterial cell disruption: with lysate (50mMNaH2PO4, 500mMNaCl, pH8.0) and resuspended thalline, with syringe by even for thalline piping and druming, avoid block throw out to produce; With biomixer Avestin cracking bacterium liquid; Centrifugal thalline after broken, 12,000rpm, 4 DEG C of centrifugal 30min, abandon supernatant, retain throw out;
(2) throw out is heavily floated on (lysate, 100 ��Ms of PMSF, 10mMEDTA, 10mMBenzamidine, 0.01%NaN in 25ml solution3); 12,000rpm, 4 DEG C, centrifugal 20min, abandons supernatant, retains throw out;
(3) repeating step (2) is once;
(4) throw out is resuspended in 25ml solution (lysate, 100 ��Ms of PMSF, 10mMMgCl, 10mMBenzamidene, 0.01%NaN3); 12,000rpm, 4 DEG C, centrifugal 20min, abandons supernatant, retains throw out;
(5) claim weight of precipitate, it is sub-packed in 1.5mlEP pipe by 1g/ pipe ,-20 DEG C of preservations.
Embodiment 5 affinity chromatography purification of Recombinant beta hemolysis fibroin
Get 1g inclusion body and it is added to (50mMNaH in 30ml denaturing soln2PO4, 500mMNaCl, 8M urea, pH8.0), room temperature for overnight; 12,000rpm, 22 DEG C, centrifugal 20min, gets supernatant, draws 20 �� l samples and treats that SDS-PAGE detects;
Post balances: gets 4mlNi-agarose and fills post, balance 10 column volumes with denaturing soln, discharges damping fluid, make liquid level higher than filler 1mm, in order to avoid dry post;
In conjunction with: the filler balanced mixes with sample liquid, rocks 1h on ice;
After completing, mixed solution joins in void column, collects Flowthrough, stays 20 �� l sample detection;
With the solution (50mMNaH of 30 times of column volumes2PO4, 500mMNaCl, 8M urea, 0.1%TritonX114, pH8.0) wash post to effluent liquid can't detect albumen, wash post with the denaturing soln of 10 times of column volumes more subsequently, stay 20 �� l to detect;
Wash-out: add imidazoles in denaturing soln, the imidazole elution of preparation 50mM, 100mM and 150mM, carries out wash-out with 5ml imidazole elution every time, and each concentration carries out 5 wash-outs;
SDS-PAGE analyzes; Result is as shown in Figure 4.
The renaturation of embodiment 6 recombinant betas-hemolysin albumen
Cut and get appropriate length dialysis tubing, with dialyzate (50mMNaH2PO4, 150mMNaCl, pH7.4) infiltrate, first to clamp one end with dialysis clip, then will treat that renaturation sample liquid joins in dialysis tubing, top clamped by dialysis clip, is positioned in 2L dialyzate, 4 DEG C of dialysis 12h;
Abandon dialyzate, then add the fresh dialyzate of 2L, continue dialysis 2h; Dialysis terminates rear 12,000rpm, 4 DEG C, and centrifugal 10min, gets supernatant;
Packing after BCA method mensuration protein concentration is also stored in-80 DEG C; SDS-PAGE analytical results is as shown in Figure 5.
Embodiment 7 recombinant betas-hemolysin protein subunit vaccine preparation
Needing according to experiment, calculate the amount of each composition of vaccine solution, make recombinant beta in vaccine-hemolysin final concentration of protein be 25 �� g/ml, wherein recombinant beta-hemolysin albumen and adjuvant ISA206VG volume ratio are 46: 54;
Being placed in thermostat water bath by mixed for dilution even good recombinant beta-hemolysin protein solution and ISA206VG adjuvant to be heated to 32 DEG C �� 1 DEG C, joined by antigen in adjuvant pipe after temperature-stable, oscillator concussion 10min carries out pre-emulsification;
Vaccine complete for pre-emulsification is positioned in the beaker filling with ice, is fixed on the ultrasonic cell disruption instrument anticipated and carries out emulsification;
After emulsification terminates, observe emulsifying effectiveness: getting part vaccine and be placed in centrifuge tube, the centrifugal 15min of 3,000rpm, vaccine is not stratified is qualified;
Detecting qualified vaccine is dispensed in 15ml centrifuge tube, mark, and sealing film sealing, is placed in 4 DEG C of preservations.
Embodiment 8 mouse immune is tested
Vaccine is taken room temperature (25 DEG C) place, make vaccine temperature return to normal temperature;
To mouse weights, grouping and mark, one group is immunity test group (n=6), immunity ��-appearance sanguinin subunit vaccine; Another group is control group (n=6), immunity PBS, and records numerical value;
Drawing 1ml vaccine with 1ml syringe, left and right back leg respectively injects 50 �� l vaccines.
Challenge viral dosage after embodiment 9 mouse immune
Choose get the mono-bacterium colony of SA (bacterial strain be this laboratory preserve HB0911-3 bacterial strain) in 5ml liquid broth, 220rpm, 37 DEG C shake bacterium and spend the night;
Volume (1ml) by mono-percent will shake the microbionation spent the night in 100ml fresh liquid broth culture, 220rpm, 37 DEG C shake bacterium and spend the night;
Being encased in 500ml centrifugal bottle by 100ml bacterium liquid, the centrifugal 10min of 8,000rpm, sucks substratum, and thalline 100mlPBS is resuspended, repeats above-mentioned steps 3 times, finally resuspended mixed even with 5mlPBS;
Count after bacterium liquid is done 10,000 times of dilutions. Concentration according to bacterium liquid, is diluted to 5 �� 10 by original bacteria liquid8CFU/ml(2MLD50);
Weighing to immune group and control group mice, one group is immunity test group (n=6), and another group records numerical value for control group (n=6);
Drawing bacterium liquid with 1ml syringe, the mouse corresponding according to each concentration bacterium carries out tail vein injection, and injection volume is 200 �� l/20g mouse.
Observe the survival state of mouse continuously, record the death time of each mouse; After attacking poison, mouse survival rate result is as shown in Figure 7.
Embodiment 10ELISA detects beta hemolysis element antibody titer
(1) bag quilt: detection albumen to the 0.5 �� g/ml diluting purifying with coating buffer (50mM carbonate buffer solution, pH9.5), on enzyme plate, every hole adds 100 �� l, and sealing film is sealed rear 4 DEG C of refrigerators placement and spent the night;
(2) wash: after taking out enzyme plate from refrigerator, put into and wash trigger washing, washings PBST;
(3) closing: every hole adds 200 �� l confining liquids (5% skimmed milk), sealing film is sealed latter 37 DEG C and is hatched 2h;
(4) preparation of samples: by known information with needing consumption, with confining liquid, serum is carried out appropriateness and dilute;
(5) wash: with (2);
(6) add sample: add dilute serum, do negative control with confining liquid simultaneously, hatch 1h for 37 DEG C;
(7) wash: with (2);
(8) add two anti-: every hole adds two anti-100 �� l of the HRP mark of appropriateness dilution, hatches 0.5h for 37 DEG C;
(9) wash: with (2);
(10) develop the color: when lucifuge, every hole adds the TMB colour developing liquid of 100 �� l, hatches 10min for 37 DEG C;
(11) terminate: every hole adds the 50 �� l stop buffer (H of 2M2SO4), termination reaction;
(12) detect: measure sample OD value in 450nm wavelength, analytical data;
(13) result analysis: the standard judging antibody positive: P/N >=2.1, OD450 >=0.1.
Claims (4)
1. the preparation method of milk cow Staphylococcus aureus beta hemolysis element subunit vaccine and application, it is characterised in that: the 1) rite-directed mutagenesis of Staphylococcus aureus protective antigen albumen ��-appearance sanguinin and clone; 2) expression and purification of recombinant beta-hemolysin albumen; 3) recombinant beta-hemolysin albumen and pharmaceutically acceptable adjuvant are fully mixed even after obtain staphylococcus aureus mastitis in dairy cows recombinant subunit vaccine.
2. streptococcus aureus protective antigen albumen beta hemolysis according to claim 1 element, it is characterised in that:
A protein that () is made up of the amino acid shown in SEQIDNO.1;
(b) aminoacid sequence in (a) through replacing, disappearance or add an amino acid or several amino acid and there is the streptococcus aureus protective antigen albumen beta hemolysis antigenic protein derivative by (a) of element;
C () recombinant beta-hemolysin protein expression system includes but not limited to intestinal bacteria, yeast, mammalian cell and insect cell etc.
3. the preparation method of milk cow streptococcus aureus beta hemolysis according to claim 1 element subunit vaccine, it is characterised in that comprise the steps:
1) rite-directed mutagenesis streptococcus aureus beta hemolysis fibroin gene;
2) by the beta hemolysis fibroin gene clone of rite-directed mutagenesis in pET28a carrier;
3) by step 2) the expression vector Transformed E .coliBL21 (DE3) that obtains, abduction delivering obtains recombinant beta-hemolysin albumen;
4) affinity chromatography purification step 3 is used) recombinant beta-hemolysin albumen of obtaining;
5) staphylococcus aureus mastitis in dairy cows recombinant subunit vaccine is obtained after the recombinant beta obtained by purifying-hemolysin albumen and pharmaceutically acceptable adjuvant (such as ISA206VG adjuvant) are fully mixed even.
4. subunit vaccine according to claim 1 is in the application prevented or in treatment staphylococcus aureus mastitis in dairy cows.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610068816.7A CN105641689B (en) | 2016-01-21 | 2016-01-21 | Preparation method and application of beta-hemolysin subunit vaccine of staphylococcus aureus of dairy cows |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610068816.7A CN105641689B (en) | 2016-01-21 | 2016-01-21 | Preparation method and application of beta-hemolysin subunit vaccine of staphylococcus aureus of dairy cows |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105641689A true CN105641689A (en) | 2016-06-08 |
| CN105641689B CN105641689B (en) | 2024-09-10 |
Family
ID=56489071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610068816.7A Active CN105641689B (en) | 2016-01-21 | 2016-01-21 | Preparation method and application of beta-hemolysin subunit vaccine of staphylococcus aureus of dairy cows |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105641689B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107224576A (en) * | 2017-03-06 | 2017-10-03 | 浙江海隆生物科技有限公司 | Vaccine of staphylococcus aureus mastitis in dairy cows subunit and its preparation method and application |
| CN115819624A (en) * | 2022-12-16 | 2023-03-21 | 广州源创生物医药科技有限公司 | Recombinant fusion protein and preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010081875A1 (en) * | 2009-01-19 | 2010-07-22 | Université de Liège | A recombinant alpha-hemolysin polypeptide of staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| CN102089005A (en) * | 2008-05-12 | 2011-06-08 | 斯特罗克斯生物制药有限责任公司 | Staphylococcus aureus-specific antibody preparations |
| CN102743747A (en) * | 2006-06-12 | 2012-10-24 | 葛兰素史密斯克蓝生物品公司 | Use of alpha-toxin for treating and preventing staphylococcus infections |
| CN102993308A (en) * | 2012-09-29 | 2013-03-27 | 重庆原伦生物科技有限公司 | Methicillin-resistant staphylococcus aureus (MRSA) vaccine recombinant protein antigen HI2 and preparation method and application thereof |
| CN103561762A (en) * | 2011-03-16 | 2014-02-05 | 明尼苏达大学董事会 | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
| CN103717234A (en) * | 2011-06-19 | 2014-04-09 | 纽约大学 | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
-
2016
- 2016-01-21 CN CN201610068816.7A patent/CN105641689B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743747A (en) * | 2006-06-12 | 2012-10-24 | 葛兰素史密斯克蓝生物品公司 | Use of alpha-toxin for treating and preventing staphylococcus infections |
| CN102089005A (en) * | 2008-05-12 | 2011-06-08 | 斯特罗克斯生物制药有限责任公司 | Staphylococcus aureus-specific antibody preparations |
| WO2010081875A1 (en) * | 2009-01-19 | 2010-07-22 | Université de Liège | A recombinant alpha-hemolysin polypeptide of staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| CN103561762A (en) * | 2011-03-16 | 2014-02-05 | 明尼苏达大学董事会 | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
| CN103717234A (en) * | 2011-06-19 | 2014-04-09 | 纽约大学 | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
| CN102993308A (en) * | 2012-09-29 | 2013-03-27 | 重庆原伦生物科技有限公司 | Methicillin-resistant staphylococcus aureus (MRSA) vaccine recombinant protein antigen HI2 and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| SEQUENCE ID: 3I41_A: "Chain A, Beta-hemolysin [Staphylococcus aureus subsp. aureus RN4220]", 《GENBANK》 * |
| 吉利伟等: "猪链球菌2型溶血素重组亚单位疫苗的研制", 《畜牧与兽医》 * |
| 杨钦等: "牛乳中金黄色葡萄球菌山东分离株(zfb)β-溶血素(hlb)的克隆、表达及溶血活性分析", 《中国农业科学》 * |
| 赫娜等: "牛源金黄色葡萄球菌突变株的筛选、鉴定及其免疫原性的研究", 《中国农业科学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107224576A (en) * | 2017-03-06 | 2017-10-03 | 浙江海隆生物科技有限公司 | Vaccine of staphylococcus aureus mastitis in dairy cows subunit and its preparation method and application |
| CN115819624A (en) * | 2022-12-16 | 2023-03-21 | 广州源创生物医药科技有限公司 | Recombinant fusion protein and preparation method and application thereof |
| CN115819624B (en) * | 2022-12-16 | 2023-12-15 | 深圳华腾生物医药科技有限公司 | Recombinant fusion protein and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105641689B (en) | 2024-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Daikoku et al. | Partial purification and characterization of the enterotoxin produced by Campylobacter jejuni | |
| CN104211804A (en) | Preparation and application of anti-staphylococcus aureus polyclonal antibody | |
| CN102181457B (en) | Clostridium difficile exotoxin B amino-terminal gene sequence with optimized codon and nucleic vaccine of clostridium difficile exotoxin B | |
| CN105641689A (en) | Preparing method and application of dairy cattle staphylococcus aureus beta-hemolysin subunit vaccine | |
| Narayanan et al. | Immunogenicity and protective effects of truncated recombinant leukotoxin proteins of Fusobacterium necrophorum in mice | |
| CN103275228A (en) | K99-987P-F41 recombinant protein and application thereof | |
| CN105646681A (en) | Preparation method and application of staphylococcus aureus alpha-hemolysin subunit vaccine for dairy cows | |
| CN102286100B (en) | SEB (staphylococcal enterotoxin B) resisting immune globulin F(ab')2 and preparation method thereof | |
| Sato et al. | New exfoliative toxin produced by a plasmid-carrying strain of Staphylococcus hyicus | |
| CN103641913B (en) | A kind of Hansenula yeast HCP preparation method for antibody, antibody and its application is made | |
| Carter | A serological study of Pasteurella haemolytica | |
| CN105126093A (en) | Helicobacter pylori tetravalent adhesion multi-epitope vaccine and preparation method thereof | |
| Throm et al. | Evaluation of an isogenic major outer membrane protein-deficient mutant in the human model of Haemophilus ducreyi infection | |
| CN107389921B (en) | A kind of preparation method and application of rabbit-anti grouper serum immune globulin HRP labelled antibody | |
| Appleyard et al. | A protective antigen from the pox-viruses: I. Reaction with neutralising antibody | |
| Walia et al. | Purification and characterization of novel toxin produced by Vibrio cholerae O1 | |
| Coulton | The ferrichrome-iron receptor of Escherichia coli K-12 antigenicity of the fhuA protein | |
| CN102935227A (en) | Newcastle disease virus hemagglutinin-neuraminidase (HN) gene subunit vaccine and preparation method thereof | |
| CN103509815A (en) | Preparation method of recombinant panda IL-2 immune adjuvant | |
| De Leeuw et al. | Aspects of heat inactivation of foot-and-mouth disease virus in milk from intramammarily infected susceptible cows | |
| CN109106946B (en) | Inactivated staphylococcus aureus vaccine for dairy cow mastitis and preparation method thereof | |
| Miller et al. | Autoimmunity in chronic experimental pyelonephritis | |
| Mahoney et al. | Immunization against babesiosis: current studies and future outlook | |
| Pirtle | A Soluble Precipitating Antigen From Hog Cholera Virus Propagated in Tissue Culture: I. Preparation and Characterization of the Antigen | |
| CN101886084B (en) | Codon-optimized H3HA/XJ3-07 gene and nucleic acid vaccine thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: China Address after: 312366 No.1 Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province (Address Declaration) Applicant after: Zhejiang Hailong Biotechnology Co.,Ltd. Address before: 312000 5th floor, building 2, science and innovation center, 398 mahuan Road, Binhai New Town, Shaoxing City, Zhejiang Province Applicant before: NOVO BIOTECH Corp. Country or region before: China |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |